OPK - OPKO Health, Inc.
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares HCA Healthcare
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in the undefined quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 shares of the biotechnology company's stock, valued at approximately $618,000. Connor Clark and Lunn Investment Management
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and other increased 208% YoY to $46.1 million in Q2, driven by a Nicoya license amendment. Also, OPKO raised its full-year 2026 revenue guidance from $530-$560 million to $560-$585 million.
OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors were also cheered by a substantial narrowing of the company's net loss. Ditto for the raised full-year revenue guidance.
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.19 per share a year ago.
OPKO Health NASDAQ: OPK reported a narrower second-quarter loss as gains tied to its diagnostics restructuring and a China commercialization agreement helped lift revenue, while the company continued to increase investment in clinical development programs.
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlights and financial results for the second quarter ended June 30, 2026. Highlights from the second quarter of 2026 and recent weeks included the following: ModeX presented data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, with plans to enter Phase 1 studies later this year or in early 2027.